Table 1 Baseline characteristics of EGC patients
Characteristics | No neoadjuvant therapy | Neoadjuvant therapy | Neoadjuvant chemotherapy | Neoadjuvant radiotherapy | Neoadjuvant chemoradiotherapy | P -value (No treatment vs. treatment) |
|---|---|---|---|---|---|---|
N | 2020 | 2008 | 498 | 39 | 1471 | |
Year of diagnosis | < 0.001 | |||||
2006–2011 | 1271 (62.9%) | 905 (44.8%) | 273 (54.8%) | 18 (46.2%) | 614 (41.7%) | |
2012–2017 | 749 (37.1%) | 1103 (55.2%) | 225 (45.2%) | 21 (53.8%) | 857 (58.3%) | |
Race | 0.425 | |||||
White | 1726 (85.4%) | 1799 (89.6%) | 419 (84.1%) | 33 (84.6%) | 1347 (91.6%) | |
Black | 99 (4.9%) | 77 (3.8%) | 28 (5.6%) | 4 (10.3%) | 45 (3.0%) | |
Others | 195 (9.7%) | 132 (6.6%) | 51 (10.3%) | 2 (5.1%) | 79 (5.4%) | |
Marital status | 0.004 | |||||
Married | 1351 (66.9%) | 1427 (71.1%) | 357 (71.7%) | 22 (56.4%) | 1048 (71.2%) | |
Others | 669 (33.1%) | 581 (28.9%) | 141 (28.3%) | 17 (43.6%) | 423 (28.8%) | |
Age | < 0.001 | |||||
≤ 60 | 656 (32.5%) | 849 (42.3%) | 220 (44.2%) | 17 (43.6%) | 612 (41.6%) | |
> 60 | 1364 (67.5%) | 1159 (57.7%) | 278 (55.8%) | 22 (56.4%) | 859 (58.4%) | |
Sex | < 0.001 | |||||
Male | 1570 (77.7%) | 1702 (84.8%) | 414 (83.1%) | 36 (92.3%) | 1252 (85.1%) | |
Female | 450 (22.3%) | 306 (15.2%) | 84 (16.9%) | 3 (7.7%) | 219 (14.9%) | |
Histology | < 0.001 | |||||
Adenocarcinoma | 1731 (85.7%) | 1602 (79.8%) | 330 (66.3%) | 31 (79.5%) | 1241 (84.4%) | |
Others | 289 (14.3%) | 406 (20.2%) | 168 (33.7%) | 8 (20.5%) | 230 (15.6%) | |
T-category | < 0.001 | |||||
T1 | 757 (37.5%) | 192 (9.5%) | 52 (10.5%) | 8 (20.5%) | 132 (9.0%) | |
T2 | 804 (39.8%) | 1136 (56.6%) | 271 (54.4%) | 24 (61.5%) | 841 (57.2%) | |
T3 | 368 (18.2%) | 592 (29.5%) | 137 (27.5%) | 6 (15.4%) | 449 (30.5%) | |
T4 | 91 (4.5%) | 88 (4.4%) | 38 (7.6%) | 1 (2.6%) | 49 (3.3%) | |
N-category | < 0.001 | |||||
N0 | 1022 (50.6%) | 596 (29.7%) | 121 (24.3%) | 13 (33.3%) | 462 (31.4%) | |
N1 | 677 (33.5%) | 1144 (57.0%) | 271 (54.4%) | 20 (51.3%) | 853 (58.0%) | |
N2 | 237 (11.7%) | 209 (10.4%) | 75 (15.1%) | 4 (10.3%) | 130 (8.8%) | |
N3 | 84 (4.2%) | 59 (2.9%) | 31 (6.2%) | 2 (5.1%) | 26 (1.8%) | |
Grade | < 0.001 | |||||
Well/Moderately differentiated | 907 (44.9%) | 728 (36.3%) | 137 (27.5%) | 13 (33.3%) | 578 (39.3%) | |
Poorly differentiated/Undifferentiated | 1053 (52.1%) | 1114 (55.5%) | 336 (67.5%) | 21 (53.9%) | 757 (51.5%) | |
Others | 60 (3.0%) | 166 (8.2%) | 25 (5.0%) | 5 (12.8%) | 136 (9.2%) | |
No. of LN examination | 0.712 | |||||
Mean | 17.5 | 17.3 | 21.0 | 12.2 | 16.3 | |
Median (range) | 15 (1–79) | 15 (1–81) | 18 (1–81) | 12 (1–31) | 15 (1–68) |